Strides Pharma Science Limited announced a robust financial performance for the fiscal year ended March 31, 2026. The company reported an EBITDA of ₹9,253 million and an operational PAT of ₹5,181 million, marking a significant 50% year-over-year growth. Driven by strong performance in ex-US markets and disciplined cost management, the board has recommended a dividend of ₹5 per share, reflecting confidence in the company’s long-term sustainable growth strategy.
Financial Performance Highlights
For the full financial year FY26, Strides Pharma Science achieved a strong operational turnaround. The company recorded revenue of ₹48,587 million, a 6.4% growth over the previous year. Operational efficiency was a major highlight, with gross margins expanding by 310 basis points to 59.7% and EBITDA margins improving by 140 basis points to 19%. This operational leverage resulted in a substantial 50.3% surge in Operational PAT, reaching ₹5,181 million.
Market Segment Analysis
Growth was primarily fueled by the company’s ex-US markets, which delivered a robust 21% year-over-year revenue growth to reach ₹22,404 million. Meanwhile, the US market remained stable, contributing ₹24,897 million in revenue, reflecting a 2% growth despite headwinds from a softer flu season in the latter half of the year. The company’s calibrated strategy continues to allow it to outperform in key international segments.
Strategic Outlook and Debt Management
The company has shown disciplined financial management, improving its Net Debt to EBITDA ratio to 1.55x, down from 1.9x in the previous fiscal year. Return on Capital Employed (RoCE) also saw a positive trend, increasing to 15.8%. Despite global geopolitical uncertainties, management remains committed to maintaining a focus on ‘difficult to manufacture’ products and sustaining long-term, profitable growth across its diverse global operations.
Source: BSE
